Vinay Prasad, controversial FDA official, abruptly departs agency Prasad’s exit ends a tumultuous tenure during which he led a reworking of agency guidelines on COVID vaccines and his office got ...

GoodRx (Nasdaq: GDRX), the leading platform for medication savings in the U.S., today announced the appointment of Laura Jensen as Chief Commercial Officer a ...

Pharmalittle: We’re reading about FDA ‘expert panels,’ knock-off weight loss drugs, and much more Europe and the U.S. agreed to a trade deal that sets a 15% tariff on pharmaceuticals ...

The Commissioner’s National Priority Vouchers aim to offer accelerated pathways to drugs that meet certain criteria, perhaps including a low price-tag. But the policy is vaguely defined and was ...

The FDA is also currently reviewing a number of other additives, with potassium bromate, propylparaben and titanium dioxide all on the FDA's list of "chemicals in the food supply under FDA review." ...

Dozens of lawmakers are urging U.S. health regulators to crack down on the booming market for knockoff weight-loss drugs amid mounting concerns over their potential safety risks.

FDA's Makary commits to reviewing abortion pill mifepristone safety data while listening to concerns, stating he has no plans for policy changes.

Conservative activist Laura Loomer has attacked Prasad as not aligned with the Trump administration's agenda. "There's not a political bone to his body.

Commissioner Marty Makary says the FDA will plow ahead with big plans on ultra process foods, dietary guidelines and expediting drug and devices reviews.